ArticleOncogene2016

MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1.

L Venturutti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.